Axsome Therapeutics, Inc. (AXSM)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Axsome Therapeutics, Inc. ("Axsome” or "the Company") (NASDAQ: AXSM). The investigation concerns whether Axsome and certain of its officers and/or directors have violated federal securities laws.
On July 14, 2021, Axsome disclosed in a filing with the U.S. Securities and Exchange Commission “that it has been notified by the U.S. Food and Drug Administration (the ‘FDA’) that the FDA is rescinding the Company’s Breakthrough Therapy Designation for its AXS-12 product candidate for the treatment of cataplexy in narcolepsy, due to the FDA approving an additional drug product for the treatment of cataplexy in narcolepsy subsequent to granting AXS-12 Breakthrough Therapy Designation.” On this news, Axsome’s stock price fell $6.60 per share, or 10.41%, to close at $56.82 per share on July 14, 2021.
If you are aware of any facts relating to this investigation, or purchased Axsome shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.